Overview


According to FutureWise analysis the market for hospital infection prevention and control is expected to register a CAGR of 8.22% from 2023-2031.

Infections are substantially caused by microorganisms similar as contagion, bacteria, and fungi or spongers. Infections can be of different types similar as stomach and intestinal infections, lung and respiratory infections, eye infections, observance infections, sanitarium acquired infections (HAIs), skin infections, and sexually transmitted infections. These infections can be caused by the cross infection from face and skin of case, outfit, and healthcare staff. Different types of products and services available to control infections include sterilization, drawing and disinfection products, defensive walls, and endoscope reclaiming products. Increase in prevalence of sanitarium- acquired infections, rise in number of surgical procedures that bear high intensity infection forestallment and control, swell in number of government mindfulness program to insure high degree infection forestallment, rise in senior population, and swell in cases of habitual conditions similar as diabetes, rotundity, cancer, heart and respiratory diseases are the major factors that are anticipated to drive the growth of the request.

In addition, rise in need for sterilization and disinfection in hospitals and conventions, technological advancements in sterilization
disinfection outfit, swell in outsourcing of sterilization services among hospitals, pharmaceutical and medical device companies, increase in product of medical nonwovens and single- use products due to swell in cases of COVID-19 are anticipated to drive the growth of the infection control request. Still, adverse goods of chemical detergents and enterprises regarding the safety of reprocessed instruments are anticipated to restrain the growth of the infection control request. Again, rise in relinquishment of single use medical nonwovens and bias is anticipated to offer economic openings during the cast period.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Hospital Infection Prevention and Control Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Hospital Infection Prevention and Control Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • 3M Company
  • Becton, Dickinson and Company
  • Ansell Ltd.
  • Belimed AG
  • Bemis Company, Inc.
  • Braun Melsungen AG
  • Cantel Medical Corp.
  • Cardinal Health, Inc.
  • Covidien plc.
  • Crosstex International, Inc.
  • Danaher Corp.
  • Diversey, Inc.
  • Johnson and Johnson

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Infection Prevention Supplies
  • Infection Prevention Equipment
  • Infection Prevention Services

By Antimicrobial Drugs

  • Anti-bacterial Drug
  • Anti-Viral Drug
  • Anti-fungal Drug
  • Vaccine

By Infections

  • Microbial infections
    • Bacterial infection
    • Viral Infection
    • Fungal Infection
  • Hospital Acquired Infection
    • Central line associated bloodstream infection (CLABSI)
    • Catheter associated Urinary Tract infection
    • Surgical site infection
    • Ventilator associated Pneumonia (VAP) infection
  • Community acquired infection
    • Methicillin resistant Staphylococcus aureus (MRSA) infection
    • Community acquired pneumonia

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Hospital Infection Prevention and Control Market By Product, By Antimicrobial Drugs, By Infections and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Hospital Infection Prevention and Control Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Hospital Infection Prevention and Control Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Hospital Infection Prevention and Control Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Hospital Infection Prevention and Control Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Infection Prevention Supplies
        2. Infection Prevention Equipment
        3. Infection Prevention Services

  • 8.   Hospital Infection Prevention and Control Market, By Antimicrobial Drugs Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anti-bacterial Drug
        2. Anti-Viral Drug
        3. Anti-fungal Drug
        4. Vaccine

  • 9.   Hospital Infection Prevention and Control Market, By Infections Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Microbial infections
         1.1. Bacterial infection
         1.2. Viral Infection
         1.3. Fungal Infection
        2. Hospital Acquired Infection
         2.1. Central line associated bloodstream infection (CLABSI)
         2.2. Catheter associated Urinary Tract infection
         2.3. Surgical site infection
         2.4. Ventilator associated Pneumonia (VAP) infection
        3. Community acquired infection
         3.1. Methicillin resistant Staphylococcus aureus (MRSA) infection
         3.2. Community acquired pneumonia

  • 10.   North America Hospital Infection Prevention and Control Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Hospital Infection Prevention and Control Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Hospital Infection Prevention and Control Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Hospital Infection Prevention and Control Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. 3M Company
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Becton, Dickinson and Company
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Ansell Ltd.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Belimed AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bemis Company, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Braun Melsungen AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Cantel Medical Corp.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Cardinal Health, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Covidien plc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Crosstex International, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Danaher Corp.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Diversey, Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Johnson and Johnson
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients